Comparison between EBV+ BCL in young patients vs EBV+ DLBCL-E
| Characteristics . | LBCL EBV+ ≤45 y (current study) (n = 46) . | LBCL EBV+ ≤50 y (Hong et al25 ) (n = 13) . | EBV+ DLBCL-E . |
|---|---|---|---|
| Male/female | 3.6:1 | 5.5:1 | 1.2-3.5:11,2,5-7,9,11,27,29 |
| Location | |||
| Nodal | 89% | NA | 18%-75%1,2,5-7,11,27 |
| Nodal + extranodal | 11% | NA | 3%-49%1,2,6,7,27 |
| Extranodal | 0% | NA | 11%-36%1,2,5,7,27 |
| B symptoms | 52% | 21% | 33%-56%1,2,7,9,10,29 |
| Elevated LDH | 67% | 69% | 41%-78%1,2,7,9,10,29 |
| IPI (HI, H) | 37% | 23% | 39%-64%1,2,7,9-11,29 |
| Advanced stage (III-IV) | 56% | 46% | 49%-64%1,2,6,7,9-11,29 |
| Immunophenotype | |||
| ABC/non-GCB | 95% | 45% | 50%-95%5-7,9-11 |
| GCB | 5% | 55% | 4%-50%2,5-7,9-11 |
| CD30 | 85% | NA | 50%-90%1,2,5,7,10,11,27,29 |
| CD15 | 9% | NA | 9%-15%1,2,10,11,27 |
| PD-L1 | 77% | NA | 100%38 |
| EBV latency | |||
| I | 0% | NA | 8%-12%5,6 |
| II | 93% | NA | 62%-77%1,2,5,6,9,10,17,29 |
| III | 7% | NA | 15%-36%1,2,5,6,9,10,29 |
| Clonal Ig | 53% | NA | 60%-83%1,6,11,27 |
| Outcome | |||
| CR | 82% | 73% | 25%-61%1,2,5,7,9-11,27 |
| Characteristics . | LBCL EBV+ ≤45 y (current study) (n = 46) . | LBCL EBV+ ≤50 y (Hong et al25 ) (n = 13) . | EBV+ DLBCL-E . |
|---|---|---|---|
| Male/female | 3.6:1 | 5.5:1 | 1.2-3.5:11,2,5-7,9,11,27,29 |
| Location | |||
| Nodal | 89% | NA | 18%-75%1,2,5-7,11,27 |
| Nodal + extranodal | 11% | NA | 3%-49%1,2,6,7,27 |
| Extranodal | 0% | NA | 11%-36%1,2,5,7,27 |
| B symptoms | 52% | 21% | 33%-56%1,2,7,9,10,29 |
| Elevated LDH | 67% | 69% | 41%-78%1,2,7,9,10,29 |
| IPI (HI, H) | 37% | 23% | 39%-64%1,2,7,9-11,29 |
| Advanced stage (III-IV) | 56% | 46% | 49%-64%1,2,6,7,9-11,29 |
| Immunophenotype | |||
| ABC/non-GCB | 95% | 45% | 50%-95%5-7,9-11 |
| GCB | 5% | 55% | 4%-50%2,5-7,9-11 |
| CD30 | 85% | NA | 50%-90%1,2,5,7,10,11,27,29 |
| CD15 | 9% | NA | 9%-15%1,2,10,11,27 |
| PD-L1 | 77% | NA | 100%38 |
| EBV latency | |||
| I | 0% | NA | 8%-12%5,6 |
| II | 93% | NA | 62%-77%1,2,5,6,9,10,17,29 |
| III | 7% | NA | 15%-36%1,2,5,6,9,10,29 |
| Clonal Ig | 53% | NA | 60%-83%1,6,11,27 |
| Outcome | |||
| CR | 82% | 73% | 25%-61%1,2,5,7,9-11,27 |
NA, not available.